National Clinical and Biological Sarcoma Database : An Initiative of the French Sarcoma Group (BCB-Sarcomes)
August 28, 2025 updated by: Institut Bergonié
The "BCB-sarcomes" Database: the Database of the French Sarcoma Group Dedicated to the Collection of Clinical and Biological Data for All Sarcomas
The BCB SARCOMES database is a clinical and biological national database dedicated to sarcoma that contains 3 main databases with specific aims: the first is the pathology database (French expert network dedicated to the management of bone sarcomas [RESOS] / French expert network dedicated to the pathology of sarcomas [RREPS]), dedicated to systematic review of mesenchymal tumor diagnostics nationwide; the second is clinical (RESOS / French expert clinical network for sarcomas [NETSARC]), collecting multidisciplinary tumor boards (MDTB) data of patients nationwide, and the third (CONTICABASE / BONE / GIST) is dedicated to collecting patients longitudinal/follow up data, with a focus on treatments of every events, and a catalogue of associated samples.
Primary objectives of BCB-SARCOMES are the following: description of the patterns of care and treatment outcomes, assessment of the prognostic factors of patients' outcomes.
With the financial support of the French National Cancer Institute [Institut National du cancer [INCa]).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
150000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Maud Toulmonde, MD
- Phone Number: 0556333333
- Email: m.toulmonde@bordeaux.unicancer.fr
Study Contact Backup
- Name: Simone Mathoulin-Pélissier, MD/PhD
- Phone Number: 05563333
- Email: s.mathoulin@bordeaux.unicancer.fr
Study Locations
-
-
-
Bordeaux, France
- Recruiting
- Institut Bergonié, Comprehensive Cancer Center
-
Contact:
- Maud Toulmonde, MD
-
Contact:
- Antoine Italiano, MD/PhD
-
Lyon, France
- Recruiting
- Centre Léon Bérard
-
Contact:
- Jean-Yves Blay, MD/PhD
-
Villejuif, France
- Recruiting
- Institut Gustave Roussy, Comprehensive Cancer Center
-
Contact:
- Axel Le Cesne, MD/PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Diagnosis of sarcoma
Description
Inclusion criteria :
- Diagnosis of sarcoma
- Diagnosis in a French Comprehensive Cancer Center
- Any age
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Patients with sarcoma
Patients with a sarcoma diagnosed in a French Comprehensive cancer Center
|
treatment as per standard of care
treatment as per standard of care
treatment as per standard of care
treatment as per standard of care
treatment as per standard of care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to next treatment (TNT)
Time Frame: 2 years
|
Time from the systemic treatment onset to the next treatment or death due to any cause, whichever comes first.
When neither death nor new systemic therapy is observed, TNT is censored at the date of last patient contact.
|
2 years
|
|
Time to next treatment (TNT)
Time Frame: 5 years
|
Time from the systemic treatment onset to the next treatment or death due to any cause, whichever comes first.
When neither death nor new systemic therapy is observed, TNT is censored at the date of last patient contact.
|
5 years
|
|
Overall survival (OS)
Time Frame: 2 years
|
Interval between diagnosis and the time of death.
When death is not observed, OS is censored at the date of last patient contact.
|
2 years
|
|
Overall survival (OS)
Time Frame: 5 years
|
Interval between diagnosis and the time of death.
When death is not observed, OS is censored at the date of last patient contact.
|
5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Maud Toulmonde, MD, Institut Bergonié, Bordeaux, France
- Study Chair: Axel Le Cesne, MD/PhD, Institut Gustave Roussy, Villejuif, FRANCE
- Study Chair: Jean-Yves Blay, MD/PhD, Centre Léon Bérard, Lyon, France
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Savina M, Le Cesne A, Blay JY, Ray-Coquard I, Mir O, Toulmonde M, Cousin S, Terrier P, Ranchere-Vince D, Meeus P, Stoeckle E, Honore C, Sargos P, Sunyach MP, Le Pechoux C, Giraud A, Bellera C, Le Loarer F, Italiano A. Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study. BMC Med. 2017 Apr 10;15(1):78. doi: 10.1186/s12916-017-0831-7.
- Toulmonde M, Bonvalot S, Meeus P, Stoeckle E, Riou O, Isambert N, Bompas E, Jafari M, Delcambre-Lair C, Saada E, Le Cesne A, Le Pechoux C, Blay JY, Piperno-Neumann S, Chevreau C, Bay JO, Brouste V, Terrier P, Ranchere-Vince D, Neuville A, Italiano A; French Sarcoma Group. Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. Ann Oncol. 2014 Mar;25(3):735-742. doi: 10.1093/annonc/mdt577.
- Blay JY, Soibinet P, Penel N, Bompas E, Duffaud F, Stoeckle E, Mir O, Adam J, Chevreau C, Bonvalot S, Rios M, Kerbrat P, Cupissol D, Anract P, Gouin F, Kurtz JE, Lebbe C, Isambert N, Bertucci F, Toumonde M, Thyss A, Piperno-Neumann S, Dubray-Longeras P, Meeus P, Ducimetiere F, Giraud A, Coindre JM, Ray-Coquard I, Italiano A, Le Cesne A. Improved survival using specialized multidisciplinary board in sarcoma patients. Ann Oncol. 2017 Nov 1;28(11):2852-2859. doi: 10.1093/annonc/mdx484.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2010
Primary Completion (Estimated)
December 31, 2030
Study Completion (Estimated)
December 31, 2035
Study Registration Dates
First Submitted
June 5, 2019
First Submitted That Met QC Criteria
June 5, 2019
First Posted (Actual)
June 6, 2019
Study Record Updates
Last Update Posted (Estimated)
September 4, 2025
Last Update Submitted That Met QC Criteria
August 28, 2025
Last Verified
August 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IB2012-BCB-SARCOMES
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.